The distribution of magnetic resonance imaging response to interferonβ-1b in multiple sclerosis

Journal of Neurology

Volumn 252, Issue 12, 2005, Pages 1455-1458

  Sormani, Maria Pia ^a,b   Bruzzi, Paolo ^b   Beckmann, Karola ^c   Kappos, Ludwig ^d   Miller, David H ^e   Polman, Chris ^f   Pozzilli, Carlo ^g   Thompson, Alan J ^e   Wagner, Klaus ^c   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c BAYER PHARMA AG   (Germany)

^d Neurologische Universitatsklinik Basel   (Switzerland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

IFN 1b; MRI response; Multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL MODEL;

BIOLOGICAL RESPONSE MODIFIERS; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; PROBABILITY;

EID: 29144495498     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0885-x     Document Type: Article

References (8)

1. European Study Group on Interferon Beta-1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of Interferon Beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
2. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F (2001) Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 57:1969-1975
3. Kuhle J, Hardmeier M, Hooghe D, Schmierer K, Polman C, Achiti I, Kappos L, EUSPMS Longterm Follow-Up Study Group (2004) 8 year follow-up of the European Study of Interferon beta-1b (EUSPMS) in Secondary Progressive MS. Neurology 62(Suppl 5):A489-A490 (Abstract)
4. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K (1999) Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 46:850-859
5. Polman CH, Uitdehaag BM (2003) New and emerging treatment options for multiple sclerosis. Lancet Neurol 2:563-566
6. Sormani MP, Bruzzi P, Miller DH, Gasperini C, Barkhof F, Filippi M (1999) Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 163:74-80
7. Spiegelhalter DJ, Thomas A, Best NG (1999) WinBUGS Version 1.2 User Manual. MRC Biostatistics Unit
8. Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H, McFarland HF (1997) Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 9:862-869